Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its price objective hoisted by stock analysts at Mizuho from $105.00 to $116.00 in a report issued on Wednesday, Marketbeat reports. The firm presently has a “neutral” rating on the stock. Mizuho’s target price indicates a potential downside of 6.53% from the company’s previous close. Other equities research […]
Sumitomo Mitsui Trust Holdings Inc. lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 1.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 283,040 shares of the company’s stock after purchasing an additional 3,122 shares during the quarter. Sumitomo […]